ENDRA Life Sciences Inc.

Cost Restructuring and Operating Performance

In fiscal year 2025, ENDRA implemented significant cost reduction measures to extend its operating runway. These measures, which included a reduction in headcount and a strategic prioritization of development activities over clinical ones, were the primary driver behind the improved financial results. Operating income showed a substantial year-over-year improvement, narrowing to a loss of $5.8 million from a loss of $10.8 million in the prior year. This 46.7% improvement demonstrates the initial impact of management's focus on conserving resources. Similarly, the net loss improved to $7.0 million from $11.5 million. The dramatic improvement in diluted earnings per share, to a loss of $8.93 from a loss of $56.94, further highlights the effect of reduced expenses on a per-share basis. The company anticipates continued public company costs but has taken decisive action to control its burn rate and focus resources on core development and regulatory strategy for its TAEUS liver application.

Liquidity and Capital Resources

Cash flow from operations remained a significant use of cash, at -$5.2 million for the year, resulting in negative free cash flow. Capital expenditures were minimal. This ongoing cash burn, coupled with management's explicit commentary, frames the company's immediate challenge. Management has stated that, based on the cash balance at year-end, ENDRA will need to raise additional capital to fund operations through the next twelve months. The need for future capital is a recurring theme, with the outlook noting that significant capital will be needed to continue planned operations. This creates a backdrop of strategic uncertainty, as the company must secure funding to advance its objectives while managing its existing cost structure.

Business Strategy and Regulatory Pathway

ENDRA's business context is shaped by trends in its target markets, including the expansion of high-end primary care networks and the increased utilization of ultrasound as a first-line diagnostic tool. In 2025, the company expanded its strategy to include a Digital Asset Treasury initiative, managed in collaboration with Arca Investment Management. This initiative seeks to optimize capital preservation and generate non-dilutive returns through investments in decentralized finance assets, representing a new strategic avenue. On the core product front, the company continues to develop its TAEUS technology and plans to incur research and development expenses for the foreseeable future as it pursues FDA approval. The regulatory pathway remains a critical focus, with resources being directed toward product improvements and regulatory strategy, particularly following the reprioritization away from clinical activities as part of the cost reduction measures.